FDA Inspection 1265132 — Renate Strehlau, PhD
The FDA completed an inspection of Renate Strehlau, PhD on Mar 14, 2025 in Johannesburg. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 14, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Johannesburg (South Africa)
Additional details
Clinical BA/BE